No Differences in Kidney Function Decline Between People With Type 2 Diabetes Starting a Sodium-Glucose Cotransporter 2 Inhibitor or a Glucagon-like Peptide-1 Receptor Agonist: A Real-world Retrospective Comparative Observational Study.

What Was Tested

The paper reports a study of Glucagon, published as an observational study.

Diabetic nephropathy represents the leading cause of end-stage kidney disease in developed countries.

The aim of this study was to compare the decline in estimated glomerular filtration rate (eGFR) among people taking a GLP1RA with that among people taking an SGLT2i in a real-world setting.

Who Took Part

According to the abstract, 478 patients were involved.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Data for 478 patients with type 2 diabetes mellitus who initiated therapy with a GLP1RA (n = 254) or an SGLT2i (n = 224) between January 1, 2018 and December 31, 2021 were extracted.

How the Study Was Run

Weight loss and drug discontinuation were also assessed.

What Was Measured

PubMed files the paper under topics including Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Diabetic Nephropathies, Hypoglycemic Agents, Kidney and Glucagon-Like Peptide-1 Receptor Agonists.

The authors tagged it with the keywords Chronic kidney disease, Diabetic nephropathy, GLP1RA, Nephroprotective action, SGLT2i and Sodium-glucose cotransporter 2 inhibitor.

What This Means in Plain Language

This is an observational study of Glucagon in 478 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Clinical therapeutics), a journal based in United States.

More context: the Glucagon compound page, all human trials.